CONFERENCE COVERAGE SERIES
Society for Neuroscience Annual Meeting 2008
Washington, DC, U.S.A.
15 – 19 November 2008
DC: Funding We Can Believe In? Perhaps, But Scientists Must Advocate
As representatives of the world’s 20 richest nations were meeting in Washington, DC, more than 31,000 scientists began arriving a few blocks away...
DC: Aβ Clearance—Roles for MBP, Transcription Factors?
Gumming up the brain years before a person may notice memory loss or other hints of Alzheimer disease, amyloid-β (Aβ) has fueled much of AD research...
DC: Primate, Mouse Studies Sustain Aβ Immunotherapy Hopes
Loaded with promise and disappointment, the roller-coaster tale of Alzheimer disease vaccine development has raised hopes and dampened some...
DC: New Neprilysin Methods Reduce Brain Aβ
Neprilysin, one of a handful of proteases known to degrade amyloid-β (Aβ), might seem an attractive therapeutic for Alzheimer disease...
DC: Dogs May Provide First Natural Animal Model for ALS
The mSOD1 mouse, harboring a mutated human superoxide dismutase (SOD1) gene, has long held the spotlight as the model of choice for ALS...
DC: More MicroRNA Implicated in Dementia
Once thought to be a simple go-between, RNA is recently attracting much more attention as an important regulator of gene expression in its own right...
DC: Amyloid-Laden Brains—What Do They Mean for Healthy Seniors?
Widely seen as the molecular trigger for a cascade of changes leading to AD, Aβ lurks within the brains of many cognitively normal seniors, too...
DC: Therapeutic Stew—Various Morsels Savored at SfN
Researchers are not shy about putting new therapies through preclinical paces...
DC: Magnifying Glass on Poisoned Mitochondria in ALS
In the spinal cord, as in life, too much of a good thing can be detrimental...
Overworked HDACs Leave Transcriptional Posts to Push DNA Repair
In discussions of what goes awry during neurodegeneration, the words genome stability, cell cycle, and DNA repair often come out in the same breath...
DC: Developing But Debatable—Deacetylase Inhibitors for CNS Disease?
While some neurodegenerative disease therapies focus on signature proteins, a growing number are addressing more fundamentally what sets neurons up for self-destruction...
DC: New γ Secretase Inhibitors Hit APP, Spare Notch
Specificity is a big issue for drug makers as side effects due to unpredicted interactions can scuttle potential pharmaceuticals...